Potentiation of photodynamic therapy in mice with recombinant human tumor necrosis factor-alpha - PubMed (original) (raw)
Potentiation of photodynamic therapy in mice with recombinant human tumor necrosis factor-alpha
D A Bellnier. J Photochem Photobiol B. 1991 Jan.
Abstract
The tumoricidal response of subcutaneously growing SMT-F adenocarcinoma implanted into syngeneic DBA/2 mice to Photofrin II-sensitized photodynamic therapy (PDT) was statistically significantly enhanced by the addition of a single dose of intravenously administered recombinant human tumor necrosis factor-alpha (rHuTNF-alpha). The interaction appeared to be approximately additive, i.e. tumor response to PDT plus rHuTNF-alpha was about the same as that observed by doubling the PDT dose. Conversely, rHuTNF-alpha did not significantly potentiate the cutaneous phototoxicity in mouse feet due to PDT. These data suggest that combination therapy should be considered for improving tumor response while retaining treatment selectivity in human malignancies.
Similar articles
- Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
Peng Q, Warloe T, Moan J, Godal A, Apricena F, Giercksky KE, Nesland JM. Peng Q, et al. Cancer Res. 2001 Aug 1;61(15):5824-32. Cancer Res. 2001. PMID: 11479222 - Hyperthermic potentiation of photodynamic therapy employing Photofrin I and II: comparison of results using three animal tumor models.
Waldow SM, Henderson BW, Dougherty TJ. Waldow SM, et al. Lasers Surg Med. 1987;7(1):12-22. doi: 10.1002/lsm.1900070104. Lasers Surg Med. 1987. PMID: 2952850 - Photodynamic therapy for thoracic malignancies.
Pass HI, Pogrebniak H. Pass HI, et al. Semin Surg Oncol. 1992 Jul-Aug;8(4):217-25. doi: 10.1002/ssu.2980080407. Semin Surg Oncol. 1992. PMID: 1386470 Review. - Molecular, cellular, and tissue responses following photodynamic therapy.
Gomer CJ, Ferrario A, Hayashi N, Rucker N, Szirth BC, Murphree AL. Gomer CJ, et al. Lasers Surg Med. 1988;8(5):450-63. doi: 10.1002/lsm.1900080503. Lasers Surg Med. 1988. PMID: 2976443 Review.
Cited by
- Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers.
Kaneko K, Acharya CR, Nagata H, Yang X, Hartman ZC, Hobeika A, Hughes PF, Haystead TAJ, Morse MA, Lyerly HK, Osada T. Kaneko K, et al. J Immunother Cancer. 2022 Sep;10(9):e004793. doi: 10.1136/jitc-2022-004793. J Immunother Cancer. 2022. PMID: 36171008 Free PMC article. - Nanotechnology-based photoimmunological therapies for cancer.
Li Y, Li X, Zhou F, Doughty A, Hoover AR, Nordquist RE, Chen WR. Li Y, et al. Cancer Lett. 2019 Feb 1;442:429-438. doi: 10.1016/j.canlet.2018.10.044. Epub 2018 Nov 24. Cancer Lett. 2019. PMID: 30476523 Free PMC article. Review. - Chemophototherapy: An Emerging Treatment Option for Solid Tumors.
Luo D, Carter KA, Miranda D, Lovell JF. Luo D, et al. Adv Sci (Weinh). 2016 May 24;4(1):1600106. doi: 10.1002/advs.201600106. eCollection 2017 Jan. Adv Sci (Weinh). 2016. PMID: 28105389 Free PMC article. Review. - Immunological aspects of antitumor photodynamic therapy outcome.
Wachowska M, Muchowicz A, Demkow U. Wachowska M, et al. Cent Eur J Immunol. 2015;40(4):481-5. doi: 10.5114/ceji.2015.56974. Epub 2016 Jan 15. Cent Eur J Immunol. 2015. PMID: 26862314 Free PMC article. Review. - The effect of ephrin-A1 on resistance to Photofrin-mediated photodynamic therapy in esophageal squamous cell carcinoma cells.
Yang PW, Chiang TH, Hsieh CY, Huang YC, Wong LF, Hung MC, Tsai JC, Lee JM. Yang PW, et al. Lasers Med Sci. 2015 Dec;30(9):2353-61. doi: 10.1007/s10103-015-1812-8. Epub 2015 Oct 8. Lasers Med Sci. 2015. PMID: 26450615
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources